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Stimulation of human platelets with the thromboxunc Al analoguc. U46619, after treatment with prostaglandin E, or forskolin. reduced the 
inhibition of ADP-evoked MI?’ influx and the release of Ca” from intracellular stores, U46619 decreased the clcvated concentration of 3’,5’eyclic 
AMP in platelets that were pretreated with prostaglandin E,. These results uggest that sccupation of prostdglandin H~thromboxane AZ receptors. 
like those for other agonists. inhibits udcnylatc yclase activity, which can contribute to the promotion of platelet aclivation. 
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1. INTRODUCTION 
Platelet activation by various agonists involves the 
production of stimulatory second messengers such as 
Ins ( 1,4,5)P3, diacylglycerol and a rise in cytosolic 
calcium concentration ([Ca’+]J [ 1,2]. Agonist-evoked 
activation is inhibited by elevation of the concentration 
of 3’,5’-cyclic AMP (CAMP) following the stimulation 
of adenylate cyclase by compounds such as prosta- 
glandins I2 and E, (PG12, PGE,) and forskolin (see e.g. 
[3-51). 
It is well established that the platelet agonists 
thrombin, ADP, vasopressin and PAF-acether can in- 
hibit adenylate cyclasc (see e.g. [6-101) as well as evok- 
ing the production of stimulatory messengers. Alpha- 
adrenergic agonists abo iiihibit the adenylate cyclasc 
[11,12], apparently via the same inhibitory GTP binding 
protein, Gi, as other agents. In contrast, there is con- 
flicting data concerning the effect of stimulation of 
prostaglandin endoperoxide PGH,/thromboxane A2 
(TxA2) receptors on platelet adenylate cyclase. Several 
earlier and recent reports describe a lack of effect of the 
stable TxA.? analogue, U46619, on basal or stimulated 
cyclase activity [13-l 61. However, other earlier reports 
present evidence for an inhibition of PGE,-stimulated 
adenylate cyclase activity by TxAl [ 171 and U46619 [1 S]. 
Further conflict comes from the recent suggestion that 
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de-sensitisation f PGH$TxA, receptors leads to a sen- 
sitisation of platelet adenylate cyclase [191. 
Here we have assessed the effects of the PGH_flxA, 
analogue, U46619, on the inhibition by PGE, or fors- 
kolin of ADP-evoked release of Ca”* from intracellular 
stores and the entry of extracellular Ca”. We present 
evidence that U46619 reduces CAMP levels in PGE,- 
treated platelets and, thus, sensitises the cells for ADP- 
evoked calcium responses. 
2. EXPERIMENTAL 
Aspirinated, fura-Xoaded human platelets were prcparcd as prcvi- 
ously dessribcd [20]. The cells were resuspcndcd in a medium of com- 
position (in mM): NaCl 145. KCI 5. MgSO, I. HEPES IO. I+glucose 
IO, pH 7.4, at 37°C. Apyrnsc (20 y&ml) was added. EGTA (1 mM) 
or I mM CaCI, and 200 ,uM MnCI, were added as required. Fura- 
Ruorcscencc from a stirred platclct suspension, thermostated at 37OC, 
was recorded in a Cairn Spcctrofluorimcter (Cairn Research, Sit- 
tingbournc. UK). For determination of [Caz’li. the ratio of Ruores- 
tense at excitation wavelengths of340 and 380 nm were calibrated as 
dcssrib4 by Grynkiewia et al. [2l]. R,, was determined by addition 
or 50 AM digitonin h the presence or I mM external Ca!+ and ki, 
by the subsequent addition of 20 mM EGTA and 20 mM TRIS base. 
All signals were corrected for autofluoresccncc determined by adding 
50 PM digitonin to cells in the presence of IO mM Mn:‘. 
The entry of divalent cAtions was determined from Ml?’ quenching 
of fura-2 fluorescence whcli XlO~M MnCI, was added to the cxtcrnal 
medium, and fluorcscencc monitored at the isobestis wavelength. 360 
nm [22]. 
For determination of CAMP, XKI ~1 samples of platclct suspension 
13 x lO”/mll were added to 500~1 of ice-cold ethanol. Cyclic AMP was \- --~, 
then extracted as described by Murray cl. al. [I91 andassaycd using 
a CAMP [‘?‘I] radioimmunoassay kit (Rianen, Du Porn, Stcvcnagc, 
UK). 
PGE, (6pM) or fonkolin @PM) were added by l.OM)-fold ilution 
from stocks in ethanol or DMSO. respectively. TIIC vehicles were 
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without effect, Cells were incubated with inhibitors for 2 min bcrore 
the lirst agonist addition, 
ADP, apyrase. aspirin, PGE, and thrombin were from Sigma 
(Poole. UK). U46619 was from Upjohn (Kalumatoo, Ml, USA). 
Forskolin and HEPES were from Calbiochem (La Jolla, CA. USA). 
3. RESULTS AND DL%XJSSlON 
3.1, Effeecm of U46519 and ADP on itthibition of internal 
Ccr” release by cAMP 
Fig. 1 shows the effect of PGE] (G@i) on the ability 
of ADP (40 PM) and U46619 (0.5 FM) to release Ca” 
from intracellular stores in fura-Zloaded human pla- 
telets. Fig la shows rises in [Ca2+]i evoked by the succes- 
sive addition of ADP and U46619. Responses with the 
additions reversed are shown in Fig. lb. After 2 min 
incubation with PGE,, the response to ADP was almost 
abolished, but the subsequent addition of U46619 
evoked a substantial rise in [Caz+li (Fig. Ic). As shown 
in Fig. Id, after pre-incubation with PGE,, U46619 
evoked almost no rise in [Ca’+li, but the response to a 
subsequent addition of ADP was partially restored. 
Similar results (not shown) were obtained when ade- 
nylate cyclase was stimulated using its specific activator, 
forskolin (2 PM) [23], 
The ability of ADP IO reduce the inhibition of the 
response voked by U46619 by PGEt was as expected, 
since ADP is known to inhibit platelet adenylate cyclase 
[8,9]. Since U46619 alleviated in part the inhibition of 
the ADP response, this agonist may have a similar inhi- 
bitory action on adenylate cyclase. 
3.2. Effecrs of U46619 md ADP on ithibirion of Mt2’+ 
er2try by CAMP 
To investigate agonist-evoked Ca” entry, fura-Z 
loaded platelets were stimulated in the presence of 1 
mM external Ca” and 200 ,uM Mn?‘. Mn2+, known to 
enter the cells by the same pathways as Ca-)+ [22,24,25], 
quenches the fluorescence of fura-2. Mn?’ entry can be 
monitored independently of changes in [Ca’-1, by excit- 
ing the dye at the isobestic wavelength of 360 nm 
[21,22]. 
Fig. 2a shows the quenching of fura- fluorescence 
evoked by the addition of 40 ,uM ADP, 0.5 j&M U46619 
and 1 U/ml thrombin. (Thrombin was added to verify 
that there was quenchable dye remaining after the addi- 
tion of the other agonists.) Fig. 2b shows the result with 
addition of U46619 before ADP. Pre-incubation of the 
platelets with 6 yM PGE, for 2 min partially inhibited 
the Mn” entry evoked by ADP (40 PM), whilst the 
entry evoked by subsequently added U46619 was hardly 
altered (Fig. 2~). In contrast, when U46619 was added 
first, the response was essentially abolished after PGE, 
p:e-incubation , whilst the subsequent addition of ADP 
evoked a large fluorescence quench. Similar results were 
obtained using 2 ,uM forskolin in place of PGE, (not 
shown). 
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Fig:. I. Effects of ADP and U46619 on the inhibition of release of Ca” 
from intracellular stores by PGE,. ADP (40yM) followed by U46619 
(OS PM), or vice versa, were added as shown to stirred suspensions 
of fura-Z-loaded platelets in the presence of I mM EGTA. (a and b) 
Changes in [Caz+li in untreated cells. (c and d) 6yM PGE, was added 
3 min before the addition of the first agonist. Traces are typical of 
those obtained in 5-G experiments. 
The findings that PGE, and forskolin were less effec- 
tive at inhibiting Mni’ (Ca?+) entry evoked by ADP 
than by U46619 are in agreement with earlier studies. 
Stopped-flow fluorimetry indicates that the platelet 
ADP response consists of two phases of Ca’+ entry [25]. 
The first phase, apparently mediated by receptor- 
operated cation channels [2619 is more resistant o in- 
hibition by forskolin, whilst the delayed component, 
which may be related to the release of Ca’” from in- 
tracellular stores, can be completely abolished using 
forskolin [20,25]. 
The Mn’+ quench experiments (Fig. 2) demonstrate 
the ability of ADP to reduce the inhibition of the 
U46619-evoked entry by PGE, and forskolin. It is also 
evident hat prior stimulation by U46619 reduces the 
inhibition of ADP-evoked entry. 
3.3. Effects of U46619 and ADP 012 CAMP iur PGE,- 
The simplest explanation of these results is that 
U46619, like ADP, is able to decrease the level of 
CAMP. We therefore determined platelet CAMP levels 
in experiments parallel to those with fura-Zloaded cells 
(see Fig. 1). The results are shown in Table 1. Prosta- 
glandin EL evoked a 4-S-fold rise in CAMP. Two 
mi.n.utes after the addition of 40 $M ADP, the level of 
CAMP was reduced to about 40% of its previous value 
and the subsequent addition of U46619 had no further 
effect. When U46619 was added as the first agonist after 
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Fig. 2. Effects of ADP and LJ46619 on the inhibition of MI?’ qucnchinp of fura- fluorcsccncc by PGE,. ADP (40 PM) followed by U466l9 (0.S 
PM), or vice versa, were added as shown to stirred suspensions of fura- 2-loaded platclcts in the prcscnce of I mM external Ca!’ and 200yM Mn”. 
Thtombin (1 U/ml) was added to indicate the availability of further quencbablc fura-2. Changes in fura- 2-fluorescence at the isobcstic wavelength 
of 360 nm are shown. In (c) and (d). 6 PM PGE, was added 2 min before the addition of the tirst agonist. Traces arc typical of those obtained 
in 5-6 experimcna. 
PGE,, the CAMP concentration was reduced to about 
60% of its pre-addition value, and reduced still further 
by the subsequent addition of ADP. When the vehicles 
alone were added after PGE,, the concentration of 
CAMP continued to slowly rise (not shown). 
The present data indicate that U46619, like other 
platelet agonists, can reduce CAMP levels in intact cells 
when elevated by PGE, or forskolin. Our results are in 
agreement with earlier reports that TxA, [17] and 
U46619 [lS] inhibit PGE,-evoked rises in CAMP in pla- 
telet-rich plasma, although other reports [15,16] failed 
to demonstrate such an effect of thromboxane. Our 
results are also in agreement with the finding that the 
ability of PAF-acether to inhibit PGI,-stimulated 
CAMP levels was abolished by blockade of cyclo- 
xygenase, suggesting that it is mediated by production 
Table I 
Effects of ADP and U46619 on PGE,-induced cyclic AMP levels 
Addition CAMP Addition CAMP 
(pmoYl0” (pmoVI0” 
Expt. A platelets) Expt. B platelets) 
EGTA 861 EGTA 7*1 
PGE, 34 + 4 PGE, 37 r 6 
ADP I3 zt I U466 19 22 +, 4 
U466 I9 I5 f 3 ADP II + I 
Platelets tirred at 37% were supplied, successively, with EGTA (1 
mM), PGE, (6pM), ADP (40pM) and U46619 (0.5 yM) (Expcrimenl 
A) or with EGTA, PGE,, U46619 and ADP (Experinrcnt Et) at 2 min 
intervals. Aliquots were taken just before each addition, and CAMP 
determined as described in section 2. Data are mean values 2 3.E. 
(n=3). Calcium responses in fura-Zloaded platelets from the same 
populations, chcckcd in parallel experiments, were similar to those in 
Fig. 1. 
of TxA? [28]. Similary, the ability of thrombin to inhibit 
adenylate cyclase has been suggested to be partly de- 
pendent on TxA2 synthesis [16]. 
Recent reports show that U46619, in contrast to 
thrombin, is without effect [13] or gives only moderate 
reduction [14] of rises in CAMP evoked by PGE,. Al- 
though this at first glance seems to contrast with our 
results, it should be noted that we added U46619 after, 
rather than before, the agent used to stimulate adenylate 
cyclase. We also found that U46619 (0.5pM) was less 
effective than ADP 140 PM) in lowering platelet CAMP 
levels (Table I) and in suppresing PGE,-induced inhibi- 
tion of Ca?’ responses (Figs. 1 and 2). Together, this 
suggests that the coupling of the PGH2/TxA2 receptors 
to the CAMP metabolising complex is less effective than 
with thrombin [6,13,14] or ADP [9]. 
It has been reported that de-sensitization of the 
PGH2/TxA2 receptor with U46619 enhances adenylatc 
cyclase stimulation by the PGI? analogue, iloprost, and 
by forskolin [19]. This effect was seen after 30 min de- 
sensitization, which may account for the opposite ffect 
of U46619 observed in our experiments. However, de- 
sensitisation to U46619 is reported to be rapid, with a 
half-time of 2-3 min [27]. Since we find decreased and 
not increased CAMP levels after 2 min treatment with 
U46619, sensitisation of the cyclase appears not to be 
the dominant effect under the conditions of our experi- 
ments. 
At present we do not know how U46619 reduces 
platelet CAMP levels, although it is possible that it in- 
hibits adenylate cylcase activity via Gi, like other 
agonists [6-lo], An alternative possibility might be the 
activation of a cyclic nucleotide phosphodiesterase, ac- 
celerating the breakdown of CAMP. Additionally, it has 
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been reported that activation of protein kinase C by 
phorbol esters results in the inhibition of platelet adc- 
nylate cyclase 128,291. However, this effect is not large 
and occurs with greater protein kinase C activation than 
is achieved with the physiological agonists thrombin 
and PAF [30]. The contribution of protein kinase C to 
the inhibitory effects of U46619 reported here is, there- 
fore, likely to be small. 
Whatever the mechanism, the ability of PGH$TxAz 
receptor occupation to decrease platelet CAMP levels, 
along with the similar actions of other agonists, would 
be of physiological significance inpromoting activation, 
as we have shown for the ADP-evoked Ca?‘ signal. 
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